Tumor-derived IL-10 impairs DC vaccine efficacy, and blockade of IL-10 production or anti-IL-10R antibody administration synergizes with DC vaccines to suppress tumor growth in tumor-bearing models [32, 166]. Here, IL10RA is linked to neoplasm.